Related Experiment Video
Updated: Jun 3, 2026
09:01
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
Inclusion body myositis: diagnosis, pathogenesis, and treatment options
Guillermo E Solorzano1, Lawrence H Phillips
1Department of Neurology, University of Virginia School of Medicine, PO Box 800394, Charlottesville, VA 22908-0394, USA. ges3b@virginia.edu
Rheumatic Diseases Clinics of North America
|March 30, 2011
Summary
Inclusion body myositis (IBM) is a common muscle disease in older adults, causing weakness in arms and legs. Research is exploring its causes and potential treatments.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Inclusion body myositis (IBM) is the most prevalent acquired myopathy affecting individuals over 50.
- It characteristically manifests as distal upper extremity and proximal lower extremity muscle weakness.
- Associated symptoms include asymmetric weakness, foot drop, and dysphagia.
Purpose of the Study:
- To review the current understanding of the pathogenesis of Inclusion body myositis.
- To discuss postulated pathogenic mechanisms underlying IBM.
- To highlight promising therapeutic candidates for IBM.
Main Methods:
- Literature review of postulated pathogenic mechanisms in IBM.
- Discussion of potential pharmacotherapies for Inclusion body myositis.
Main Results:
- The precise pathogenesis of IBM remains unclear.
- Several potential mechanisms contributing to IBM are under investigation.
- No definitive pharmacotherapy is currently established for IBM.
Conclusions:
- Further research into IBM pathogenesis is crucial.
- Exploration of novel therapeutic strategies is ongoing.
- Promising drug candidates warrant further investigation for IBM treatment.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:21Myocarditis I: Introduction
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...